J
Jatin Patel
Researcher at GlaxoSmithKline
Publications - 19
Citations - 1021
Jatin Patel is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Placebo & Mepolizumab. The author has an hindex of 10, co-authored 17 publications receiving 915 citations.
Papers
More filters
Journal ArticleDOI
Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial
Alex Straumann,Sébastien Conus,Pascale Grzonka,Hirohito Kita,Gail M. Kephart,Christian Bussmann,Christoph Beglinger,Deborah A. Smith,Jatin Patel,Margaret Byrne,Hans-Uwe Simon +10 more
TL;DR: Mepolizumab significantly reduced eosinophil numbers in oesophageal tissues in adult patients with active EoO, and changes in the expression of molecules associated with oesphageal remodelling were reversed.
Journal ArticleDOI
CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial
William J. Sandborn,Brian G. Feagan,Graham L. Radford-Smith,A Kovacs,Robert Enns,A. Innes,Jatin Patel +6 more
TL;DR: CDP571 is modestly effective for short but not long term treatment of unselected patients with moderate to severe Crohn’s disease and post hoc analysis suggests both short and long term efficacy of CDP571 in patients with elevated baseline CRP (⩾10 mg/l).
Journal ArticleDOI
Novel targeted therapies for eosinophilic disorders.
Michael E. Wechsler,Patricia C. Fulkerson,Bruce S. Bochner,Gail M. Gauvreau,Gerald J. Gleich,Tim Henkel,Roland Kolbeck,Sameer K. Mathur,Hector Ortega,Jatin Patel,Calman Prussin,Paolo M. Renzi,Marc E. Rothenberg,Florence Roufosse,Dagmar Simon,Hans-Uwe Simon,Andrew J. Wardlaw,Peter F. Weller,Amy D. Klion +18 more
TL;DR: An overview of eosinophil biology with an emphasis on potential targets of pharmacotherapy is provided and a summary of potential eosInophil-targeting agents, including those in development, in clinical trials, or approved for other disorders are provided.
Clinical reviews in allergy and immunology
Donald Y.M. Leung,Dennis K. Ledford,Michael E. Wechsler,Patricia C. Fulkerson,Bruce S. Bochner,Gail M. Gauvreau,Gerald J. Gleich,Tim Henkel,Roland Kolbeck,Sameer K. Mathur,Hector Ortega,Jatin Patel,Calman Prussin,Paolo M. Renzi,Marc E. Rothenberg,Florence Roufosse,Dagmar Simon,Hans-Uwe Simon,Andrew J. Wardlaw,Peter F. Weller,Amy D. Klion +20 more
TL;DR: An overview of eosinophil biology with an emphasis on potential targets of pharmacotherapy is provided and a summary of potential eosInophil-targeting agents, including those in development, in clinical trials, or approved for other disorders are provided.